This company has been acquired
Paratek Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Paratek Pharmaceuticals has been growing earnings at an average annual rate of 14.5%, while the Pharmaceuticals industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 50.2% per year.
Key information
14.5%
Earnings growth rate
27.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 50.2% |
| Return on equity | n/a |
| Net Margin | -35.4% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Revenue & Expenses Breakdown
How Paratek Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 177 | -63 | 157 | 0 |
| 31 Mar 23 | 167 | -66 | 151 | 0 |
| 31 Dec 22 | 160 | -64 | 146 | 0 |
| 30 Sep 22 | 117 | -89 | 136 | 0 |
| 30 Jun 22 | 111 | -86 | 128 | 0 |
| 31 Mar 22 | 139 | -59 | 125 | 0 |
| 31 Dec 21 | 130 | -59 | 119 | 0 |
| 30 Sep 21 | 114 | -52 | 100 | 0 |
| 30 Jun 21 | 104 | -54 | 95 | 0 |
| 31 Mar 21 | 55 | -87 | 89 | 0 |
| 31 Dec 20 | 47 | -97 | 90 | 0 |
| 30 Sep 20 | 40 | -99 | 87 | 0 |
| 30 Jun 20 | 30 | -111 | 90 | 0 |
| 31 Mar 20 | 23 | -121 | 89 | 0 |
| 31 Dec 19 | 17 | -129 | 89 | 0 |
| 30 Sep 19 | 25 | -124 | 93 | 0 |
| 30 Jun 19 | 21 | -124 | 83 | 0 |
| 31 Mar 19 | 19 | -120 | 75 | 0 |
| 31 Dec 18 | 17 | -112 | 64 | 0 |
| 30 Sep 18 | 5 | -111 | 50 | 0 |
| 30 Jun 18 | 5 | -101 | 45 | 0 |
| 31 Mar 18 | 13 | -89 | 40 | 0 |
| 31 Dec 17 | 13 | -89 | 37 | 0 |
| 30 Sep 17 | 8 | -94 | 32 | 0 |
| 30 Jun 17 | 8 | -96 | 30 | 0 |
| 31 Mar 17 | 0 | -108 | 28 | 0 |
| 31 Dec 16 | 0 | -112 | 26 | 0 |
| 30 Sep 16 | 0 | -106 | 26 | 0 |
| 30 Jun 16 | 0 | -106 | 25 | 0 |
| 31 Mar 16 | 0 | -91 | 22 | 0 |
| 31 Dec 15 | 0 | -71 | 20 | 0 |
| 30 Sep 15 | 4 | -61 | 16 | 0 |
| 30 Jun 15 | 4 | -42 | 13 | 0 |
| 31 Mar 15 | 4 | -29 | 10 | 0 |
| 31 Dec 14 | 4 | -20 | 6 | 0 |
| 30 Sep 14 | 0 | -12 | 4 | 0 |
| 30 Jun 14 | 1 | -11 | 3 | 0 |
| 31 Mar 14 | 0 | -11 | 3 | 0 |
| 31 Dec 13 | 0 | -11 | 3 | 0 |
| 30 Sep 13 | 1 | -37 | 10 | 0 |
| 30 Jun 13 | 1 | -41 | 10 | 0 |
| 31 Mar 13 | 3 | -45 | 10 | 0 |
| 31 Dec 12 | 3 | -50 | 10 | 0 |
| 30 Sep 12 | 4 | -28 | 4 | 0 |
Quality Earnings: PRTK is currently unprofitable.
Growing Profit Margin: PRTK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRTK is unprofitable, but has reduced losses over the past 5 years at a rate of 14.5% per year.
Accelerating Growth: Unable to compare PRTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: PRTK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.